Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Naked short shares!!! What happens if we purchase shares that were sold short. If the shares never existed but were sold, does the buyer actually own the shares that were purchased??? Or does the buyer only own the shares once the short seller purchases the shares to replace the shorted sale???
I’m so glad that you will continue posting here next year now. Your posting is what keeps so many of us on a positive note. You keep it real.
Merry Christmas Flipper, and to everyone else on this board.
I am going to say 7/21/22 . Just 8 years,8 months, and 8 days after my first purchase of NWBO on November 13th of 2013. It has been a long long road.
Living here in Lubbock Texas, we were excited with Texas Tech making it to the Final Four. Who knew that the Championship game was going to be such a close one, and having to go into overtime. I really thought that Tech had the game there for a while near the end. Now we can just hope for next year.
I just read this on Fox News. Sounds a lot like they are nearly copying Direct.
How new cancer 'vaccine' fights tumors throughout the body
https://www.foxnews.com/health/how-new-cancer-vaccine-fights-tumors-throughout-the-body
202-841-7909 is the cell phone number for Les. I also have his home number, but don’t feel right about giving it out.
We are both in the same boat. I sincerely believe that we will end up well loved by all. And we may not have much longer to wait.
I think about posting fairly often, but I hold back knowing that I can contribute little to the debates, and don't want to get into arguments with some of the negative posters when I know that they are wrong about certain things.
I never invest in any stock unless I have done my duty to myself by studying all I can about a company. I felt strong about NWBO when I originally purchased and am feeling even stronger now that we are near the finish line. I look forward to the time when my friends and family members reap some of the rewards from this stock when they are able to sell what I had recommended to them.
But most of all, I look forward to the cancer patients having a program that will be able to help most of them, where there is little hope today. I have lost several family members and friends to cancer, and I am tired of doctors telling people that there is nothing else that can be done for them. Telling them to go home and die!!!
I have just a little under a third of a million dollars invested in NWBO. I have purchased at various levels, from $7.20 and down, but my average is $1.65 per share. I am not greedy, but I did average down some to keep my leverage. I will do well enough in the end.
I mainly just sit back and read the various writings each day. I have nothing valuable to add to the discussions. I will say that it has been a very interesting 5 1/2 years though. When I first got involved, I studied all that I could about this company and their goals. I made my decision to invest in NWBO, and have not regretted it. I know the present day value of this company is not where it should be, but the majority of the falling value has been out of their control. I still feel that in the end, this company will achieve their goal and we will get approved by the various agencies on both continents. The cancer victims will be the true winners. but we should do quite well ourselves.
After all the warrants are exercised, there will be over 950 million shares. It is easier to equate by just saying a billion.
In 2013 when I first started investing in NWBO there was only 43.4 million shares.
What about the naked short shares. When I talked with LG several months ago, he referred to a HUGE amount of Naked Short Shares that are not accounted for on any of those websites.
IMO, they did not de-list from Nasdaq so they could get the financing. They had to get the financing because they had de-listed.
Quote: Ceasing to be listed or quoted on Nasdaq will constitute a "Fundamental Change" under the terms of the Company's Convertible Senior Notes that were issued in August, 2014 and are otherwise due in August, 2017. Following this change, the Company will have a period of 20 business days, ending in January, within which the Company is obligated to make an offer to repurchase the Notes in accordance with the terms of the indenture relating to the Notes. There is approximately $11.0 million in aggregate principal amount outstanding. The Company believes that it has several options for addressing this obligation, and will be evaluating those options over the coming weeks, although there can be no assurance that such options will be available or will be on acceptable terms. If the Company fails to satisfy its obligation, that would result in an event of default under the Notes.
New message from Les,
December 23, 2015 NASDAQ:NWBO
Dear XXX,
As you will see in the attached release from this morning, we have entered into a $12.6 million financing from healthcare focused institutional investors. This financing augments our resources and we believe it will help position us to be ready for a strong and busy start to the New Year.
Thank you, as always, for your support, patience and interest.
And from our family to yours, we wish you a happy and healthy holiday break.
Sincerely,
Leslie J. Goldman
Senior Vice President for Business Development
Embargoed for release at 9:00 a.m. US EST on Wednesday, December 23, 2015
NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $12.6 MILLION
BETHESDA, Md., December 23, 2015 - Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with healthcare focused institutional investors for a registered direct offering with gross proceeds of $12.6 million. In the offering, the Company is selling an aggregate of 3.5 million shares of common stock at a purchase price of $3.60 per share. The investors will also receive warrants to purchase up to 1.75 million shares of common stock with an exercise price of $4.50 per share. The warrants will become exercisable on the 6-month anniversary of issuance, and will have an exercise period of 5 years following the initial exercise date. The placement is expected to close on or about December 29, 2015, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction.
The securities described above are being offered pursuant to a shelf registration statement (File No. 333-207976), which was declared effective by the United States Securities and Exchange Commission ("SEC") on December 22, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or by request at H.C. Wainwright & Co., LLC, at placements@hcwco.com.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM), which is on a partial clinical hold in regard to new screening of patients. GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all inoperable solid tumors cancers, with a primary efficacy endpoint of tumor regression. It has completed enrollment in the Phase I portion of the trial. The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer. The Company conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania. In Germany, the Company has also received approval of a 5-year Hospital Exemption for the treatment of all gliomas (brain cancer) patients outside the clinical trial.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ongoing ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing and expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Contacts
Les Goldman
202-841-7909
lgoldman@nwbio.com
CLICK HERE TO DOWNLOAD PRESS RELEASE FROM THE NORTHWEST BIOTHERAPEUTICS WEBSITE
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane
Suite 800
Bethesda, MD 20814 (240) 497-9024
www.nwbio.com
@NorthwestBio
DO YOU BELIEVE????
Woodford is down on paper much more than any of us, and he still likes NWBO. I am down $463,481.60 on paper as of yesterday, from the high back in July, but I still like NWBO also. He and I have a lot in common. We have lost nothing, because we have not sold. We stand to make plenty when this gets approved.
I get tickled when I see all the moaning and groaning going on because the share price is going south. If you don't sell, you don't loose. Simple as that!!!!!!
Now, if we don't get approved, then we loose. But who believes that is going to happen. You would not be a shareholder unless you believed we will get approved, then we win. Simple as that!!!!!.
DO YOU BELIEVE?????
Thanks Flipper44. I thought I might have just imagined what I wanted to hear, during that conference.
I really appreciate all that you do here on IHUB, for all of us Long Investors. I have learned a lot from you.
I've been out for a couple of weeks, due to health issues, but I was wondering if I missed something while gone. I thought that when Linda Powers spoke at her last conference, she stated that we would get all data, up to date, on DCVax-D, before March ended. Did I not interpret that correctly? I did see where they released data on the 51 GBM patients. I am going back and reading the past posts on here, but I am afraid that I am about 2 weeks behind. Any info on this would help me.
Thanks
MD Anderson is partnering with Interexon and Ziopharm to fight cancer with their products.
Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact
4:24 PM ET 1/13/15 | PR Newswire
4:02 PM ET 1/14/15
Symbol Last % Chg
XON
37.30 31.48%
ZIOP
8.87 54.53%
Real time quote.
Intrexon Corporation (NYSE: XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (NASDAQ: ZIOP), today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
The licensed technologies arise from the laboratory of Laurence Cooper, M.D., Ph.D., professor of pediatrics at MD Anderson and Perry Hackett, Ph.D., professor within the College of Biological Sciences at Minnesota. The Cooper and Hackett laboratories have pioneered the design and clinical investigation of novel chimeric antigen receptor (CAR) T cell therapies using non-viral gene integration platforms. MD Anderson has built on this technology to deliver patient-derived T cells, as well as innovative approaches to generating products for universal off-the-shelf applications. When combined with Intrexon's technology suite and ZIOPHARM's clinically tested RheoSwitch Therapeutic System(R) interleukin-12 modules, the resulting proprietary methods and technologies may help realize the promise of genetically modified CAR T cells by tightly controlling cell expansion and activation in the body, minimizing off-target effects and toxicity while maximizing therapeutic efficacy.
"Genetically engineering our patients' immune-system T cells to efficiently attack and destroy cancer cells represents one of the most exciting approaches with curative potential in oncology today," MD Anderson President Ron DePinho, M.D., said. "We believe coupling MD Anderson's unique CAR T cell approach with the powerful technologies of ZIOPHARM and Intrexon will allow us to build T cells that hit cancer harder, with greater precision, under tighter control and with potentially fewer side effects for patients. This agreement ranks as one of MD Anderson's most substantial collaborations and will provide significant resources to fuel its mission of Making Cancer History(R)."
"We are proud to see Perry Hackett's discovery and development work on Sleeping Beauty, a non-viral DNA plasmid-based gene transfer system, in conjunction with Dr. Cooper's expertise in immunotherapies, provide this breakthrough in oncology" said Brian Hermann, Vice President of Research at the University of Minnesota.
Employing novel cell engineering techniques and multigenic gene programs, the collaboration will implement next-generation non-viral adoptive cellular therapies based on designer cytokines and CARs under control of RheoSwitch(R) technology targeting both hematologic and solid tumor malignancies. The synergy between the platforms will be leveraged to accelerate a promising synthetic immunology pipeline, with up to five CARs expected to enter the clinic in 2015 and off-the-shelf programs initiating in 2016.
"It is a shared vision to maximize the speed and breadth of multigenic innovation for patients through the use of nimble, non-viral DNA cell manufacturing strategies that can further overcome viral packaging constraints and economic limitations," stated Gregory Frost, Ph.D., Senior Vice President and Head of Intrexon's Health Sector. "Collectively, this will assemble the most advanced set of technologies to empower the strongest adoptive cell therapy pipeline that can drive innovation through multiple horizons and patient populations."
Cooper, Hackett and colleagues developed a non-viral DNA plasmid-based gene transfer system to modify T cells by creating a CAR that recognizes and binds to a specific cell surface protein on targeted malignant cells. The testing of this system at MD Anderson in humans paves the way for the rapid design and implementation of modified T cells that can be infused into patients with many types of malignancies.
Work continues in conjunction with MD Anderson's Moon Shots Program, an ambitious initiative to accelerate the conversion of scientific discoveries into clinical advances and significantly reduce cancer deaths, first targeting eight types of cancer. Cooper leads the Applied Cellular Therapeutics platform for the moon shots, providing expertise and new cellular therapy capabilities for both blood and solid tumor cancers. Clinical trials using non-viral adoptive cellular therapies are either under way or planned for specific moon shot cancers.
The shared infrastructure between MD Anderson, Intrexon and ZIOPHARM enables two approaches to deliver these commercially viable T cells to the bedside. The first develops a point-of-care approach with rapid assembly and infusion of autologous T cells. The second arises from the universal donor platform to infuse off-the-shelf T cells using innovative activation and targeting gene programs that precisely recognize and systemically combat malignancies. The collaboration will advance these platforms in parallel with the most effective CAR-T products tested at MD Anderson graduating to multicenter trials.
"The promise of controlled, cell-based immuno-oncology therapy is that we can achieve dramatic, long duration anti-cancer results while keeping patients out of intensive care during treatment. As importantly, we can reproduce these results in a globally scalable and economically viable way," remarked Jonathan Lewis, M.D., Ph.D., Chief Executive Officer of ZIOPHARM Oncology. "The MD Anderson Cancer Center has long been a leader in cancer therapy, in terms of innovation, patient care, and the highest quality research. As part of our commitment to this important partnership and the acceleration of translational medicine, ZIOPHARM will build a base of operations in Houston to join and collaborate with the academic and medical community around this world-class institution."
"The human application of T cell therapies provides cancer patients with new hope, and the alignment of MD Anderson's immunotherapy and translational programs with Intrexon and ZIOPHARM will help make that hope a reality," Cooper said. "These two interconnected companies have first-in-class genetic tools and systems to reprogram cells and the management and regulatory expertise to undertake development of potent and focused cell-based immunotherapies."
Under the terms of the agreement, MD Anderson shall receive consideration of $100 million; $50 million from each Intrexon and ZIOPHARM, payable in shares of their respective common stock, as well as a commitment of $15 to $20 million annually over three years for researching and developing the technologies. The parties will enter into additional collaboration and technology transfer agreements to accelerate technology and clinical development. Further details on the terms of the transaction will be available within the current reports on Form 8-K filed today by Intrexon and ZIOPHARM.
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer Sectors to create biologically-based products that improve the quality of life and the health of the planet. Through the company's proprietary UltraVector(R) platform and suite of technologies, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector(R) platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA(R), and we invite you to discover more at www.dna.com.
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System^(R) technology to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The Company's synthetic immuno-oncology programs in collaboration with Intrexon also include chimeric antigen receptor T cell (CAR-T) approaches.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. It is one of only 41 comprehensive cancer centers designated by the National Cancer Institute (NCI). For the past 25 years, MD Anderson has ranked as one of the nation's top two cancer centers in U.S. News & World Report's annual "Best Hospitals" survey. It receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
New Letter from LG:
January 8, 2015 NASDAQ:NWBO
Dear XXXXXXX
Hope you had a wonderful Holiday season and New Year.
We are excited about 2015 and all that lies ahead for NW Bio.
To kick the New Year off, you may want to catch our CEO, Linda Powers' update from the Biotech Showcase 2015 Conference in San Francisco next Monday at 5 PM PST.
The attached release provides the weblink to the presentation.
It is certainly a good time to be helping lead the growing interest in immune therapy.
Thanks for your continuing support and interest.
Sincerely,
Leslie J. Goldman
Senior Vice President for Business Development
NW BIO TO PRESENT AT BIOTECH SHOWCASE CONFERENCE
BETHESDA, MD, January 8, 2015 - Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that CEO Linda Powers will present at the Biotech Showcase conference in San Francisco.
The presentation will take place on Monday, January 12, at 5:00 p.m. PST in the Mission II Room at the Parc 55 Wyndham, 55 Cyril Magnin Street. There will be a live audio webcast of the presentation available at nwbio.com/webcasts/ Ms. Powers will provide an update about the Company's DCVax programs and plans for 2015, as well as a summary of key accomplishments in 2014.
Biotech Showcase is an investor and partnering conference designed to provide biotechnology and life sciences companies with an opportunity to connect with investors and pharmaceutical executives.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all inoperable solid tumors cancers, with a primary efficacy endpoint of tumor regression. It has completed enrollment in the Phase I portion of the trial. The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer. The Company conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania. In Germany, the Company has received approval of a 5-year Hospital Exemption for the treatment of all gliomas (brain cancer) patients outside the clinical trial.
Les Goldman
202-841-7909
lgoldman@nwbio.com
Farrell Kramer (Media)
212-710-9685
farrell.kramer@mbsvalue.com
Thanks Flipper44,
It is a helpless feeling, knowing what we have with Direct, and not being able to get it out to the people who need it. I will never understand why the FDA requires such a long period of time for something with virtually no side effects, to get approval.
I "Do" know the reasons behind it, but too many people will die before they will be able to get treatment.
Well said Sentiment.
8:00 am Eastern Time
Thanks Flipper, I hope, for all the patients in the trial, that the Doctors are seeing great results, and this will be reported during the conference. This is what I am praying for. There have been way too many deaths due to Cancer, and I have lost too many relatives and friends to it also. Hopefully this treatment will be available to all within the next 1-2 years. I just want it to be approved sooner than later.
Flipper, Do you think that Direct could get approval from the FDA after trial 1/2, without having to go to trial 3?
This is my thinking:
Percentage of Patients have complete Tumor Death.
30%-40%= FDA would make NWBO do phase 3 trial
50%-60%= 50% chance FDA would approve after phase 1/2
70%-80%= 75% chance FDA would approve after phase 1/2
90%-100%= 100% chance FDA would approve after phase 1/2
These patients had ZERO chance of survival without Direct, and to me it only makes sense that the FDA would want to get this out to as many people as possible, as quickly as possible, being as there is no side effects other than small fever.
The shorts definately need to be buying to cover, but who would have sold that large amount?
My thoughts exactly. Who could have pre-planned the execution at that large amount of shares, and why. That was over 2 million dollars worth of shares. ??????????
499,000 shares purchased at 10:20 @4.10 per share. How did that happen without jumping the share price up?
Thank you Highwayman4life, for sharing with us your conversation with LG. It gives us more confidence in NWBO, with LG openly discussing what is going on. It is hard for all of us to keep a possitive attitude when the SP keeps slipping.
I, like a lot of you, are long on NWBO. I have a significant amount of shares, and have gotton several friends and relatives to invest also. They have not done as much research and are not as convinced as I am about what this will mean for the patients, and for us as investors. Your conversation gives me more info to share with them, as to what we can look forward to in the next few months.
Thanks!!! To you, and the rest of the Long investors of this board for all that you contribute.
I firmly believe that within 1-2 years, NWBO will be in the $250.00 - $400.00 range. I can afford to wait for that much difference, and pay the lesser % of tax.
I just put in a limit sell order for 1000 shares in E-Trade for $100.00 each, and E-Trade accepted the order.
5 minutes later put in a limit sell order for 10,000 shares for $150.00 each, and E-Trade accepted it also. I did not get any message stating the order limit was too large.
I hope neither one sells before I can cancel, because I would hate to pay 39% taxes selling now, insted of 20% capital gain taxes by waiting until november.
You are wrong. Yes, it is a small company that is not well known. They have come a long way over the last decade, and their time is coming. The Public is not aware yet of just how great NWBO is, but they will.
NWBO will become the go-to, when cancer is found in a person. They have helped so many people already, but they are just getting started. It may take a while, but "L" will get approved. Look at the results found so far, but the best part is minimal side effects(high temperature). The FDA will have to approve it.
Then we have "Direct" coming, not far behind. Doctors at M.D.Anderson are seeing great things happening with "D". Maybe after ASCO, we will have their help with the FDA, in getting this out as soon as possible. ASCO carries a lot of weight.
Everyone just needs to stay calm and steady. NWBO will prevail.
I'm new to the board here, but have been following it for a couple of months. I got involved with NWBO stock after the Fox News interview in November, and am very glad that I was watching it that night.
Cancer affects each and everyone of us. I can count at least eight relatives and friends that have died due to one form of cancer or another. After doing as much research as I could on NWBO, I started buying shares. I firmly believe that NWBO has the answer to help extend people's lives, if not totaly cure them.
There are many people here that have done very extensive background work on NWBO, and I am encouraged that so many feel the way I do about this stock.
I owned a large amount of shares due to the my research, and added more after reading all of yall's comments. (Lubbock Texas slang)
Thank you, to all of you here.
P.S.
Read the comments section under the Seaking Alpha article. Very interesting to see Adam F commenting about Larry's article.